Tìm theo
Atracurium
Các tên gọi khác (2) :
  • 1-[(3,4-Dimethoxyphenyl)methyl]-2-[3-({5-[(3-{1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl}propanoyl)oxy]pentyl}oxy)-3-oxopropyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium
  • ATRACURIUM
Thuốc giãn cơ và tăng trương lực cơ
Thuốc Gốc
Small Molecule
CAS: 64228-79-1
ATC: M03AC04
ĐG : Baxter International Inc. , http://www.baxter.com
CTHH: C53H72N2O12
PTK: 929.145
A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents. [PubChem]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
Phân tử khối
929.145
Monoisotopic mass
928.508525778
InChI
InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2
InChI Key
InChIKey=YXSLJKQTIDHPOT-UHFFFAOYSA-N
IUPAC Name
1-[(3,4-dimethoxyphenyl)methyl]-2-[3-({5-[(3-{1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl}propanoyl)oxy]pentyl}oxy)-3-oxopropyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium
Traditional IUPAC Name
atracurium
SMILES
COC1=C(OC)C=C(CC2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3C2CC2=CC(OC)=C(OC)C=C2)C=C1
Độ tan chảy
85-90
Độ hòa tan
Miscible
logP
-0.96
logS
-7.6
pKa (strongest acidic)
19.02
pKa (Strongest Basic)
-4.1
PSA
126.44 Å2
Refractivity
280.68 m3·mol-1
Polarizability
104.67 Å3
Rotatable Bond Count
26
H Bond Acceptor Count
10
H Bond Donor Count
0
Physiological Charge
2
Number of Rings
6
Bioavailability
0
MDDR-Like Rule
true
Dược Lực Học : Atracurium is a nondepolarizing skeletal muscle relaxant. Atracurium can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. The duration of neuromuscular block produced by Atracurium is approximately one third to one half the duration of block by d-tubocurarine, metocurine, and pancuronium at initially equipotent doses. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of Atracurium. Repeated administration of maintenance doses of Atracurium has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results.
Cơ Chế Tác Dụng : A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents. [PubChem] Atracurium antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.
Dược Động Học :

▧ Half Life :
The elimination half-life is approximately 20 minutes.
Độc Tính : Excessive doses can be expected to produce enhanced pharmacological effects. Overdosage may increase the risk of histamine release and cardiovascular effects, especially hypotension.
Chỉ Định : For use, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Tương Tác Thuốc :
  • Amikacin The agent increases the effect of muscle relaxant
  • Aminophylline Theophylline decreases the effect of muscle relaxant
  • Azathioprine The agent decreases the effect of the muscle relaxant
  • Carbamazepine Decreases the effect of muscle relaxant
  • Clindamycin The agent increases the effect of muscle relaxant
  • Colistimethate Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B).
  • Fosphenytoin Phenytoin decreases the effect of muscle relaxant
  • Gentamicin The agent increases the effect of muscle relaxant
  • Lincomycin The agent increases the effect of muscle relaxant
  • Mercaptopurine The agent dereases the effect of the muscle relaxant
  • Netilmicin The agent increases the effect of muscle relaxant
  • Oxtriphylline Theophylline decreases the effect of muscle relaxant
  • Phenytoin Phenytoin decreases the effect of the muscle relaxant
  • Piperacillin The agent increases the effect of the muscle relaxant
  • Quinidine The quinine derivative increases the effect of the muscle relaxant
  • Quinine The quinine derivative increases the effect of the muscle relaxant
  • Theophylline Theophylline decreases the effect of the muscle relaxant
  • Tobramycin The agent increases the effect of the muscle relaxant
Liều Lượng & Cách Dùng : Liquid - Intravenous
Solution - Intravenous
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
Đóng gói
... loading
... loading